Thomas Durcan

Principal Investigator

SGC Neuro

Originally from Dublin, Ireland, Thomas Durcan, PhD has been at the Montreal Neurological Institute (The Neuro) since 2007. As an Associate Professor at The Neuro and McGill University (, his research focus is on applying patient-derived induced pluripotent stem cells (IPSCs) towards the development of phenotypic discovery assays and 3D mini-brain models ( for both neurodegenerative and neurodevelopmental disorders.

As Director of the EDDU at The Neuro, he oversees a team of over 40 research staff and students, committed to applying novel stem cell technology, combined with CRISPR genome editing, mini-brain models and new microfluidic technologies towards elucidating the underlying causes of these complex disorders. Combined with new approaches in the group towards building multi-omics profiles on the patient-derived IPSC cells, the long-term strategy is to identify new personalized precision therapies. Dr. Durcan's academic research program is funded by a CIHR program grant and USA Department of Defense Research grants.

Publications TDurcan



Identification of highly specific antibodies for Serine/threonine-protein kinase TBK1 for use in immunoblot, immunoprecipitation and immunofluorescence.
Alshafie W, Fotouhi M, Shlaifer I, Ayoubi R, Edwards AM, Durcan TM, McPherson PS, Laflamme C
F1000Res. 07.12.2022 11:977. doi: 10.12688/f1000research.124632.2
PMID: 36415206



Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72.
Laflamme C, McKeever PM, Kumar R, Schwartz J, Kolahdouzan M, Chen CX, You Z, Benaliouad F, Gileadi O, McBride HM, Durcan TM, Edwards AM, Healy LM, Robertson J, McPherson PS
Elife. 15.10.2019 8:. doi: 10.7554/eLife.48363
PMID: 31612854

glqxz9283 sfy39587stf02 mnesdcuix8